Immunohistochemical Expression of COX-2 in Feline Injection Site Sarcoma

Magi, Gian Enrico; Mari, Subeide; Renzoni, Giacomo; Rossi, Giacomo

doi:10.1016/j.jcpa.2010.09.110

Cited by 5 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors conclude that these findings may be useful in predicting the sensitivity of FISS to treatment with COX-2 inhibitors, but their potential therapeutic use could be restricted to tumours with a lower degree of anaplasia. These results were in accordance with those of the investigations of Magi et al (35) and Carneiro et al (11), who found COX-2 expression in 97.0% (30/31) and 61.9% (13/21) of FISS cases, respectively, but in contrast to those of Beam et al (7), who did not find COX-2 expression in any FISS cases.…”

Section: Expression Of Cox-2 In Canine and Feline Tumourssupporting

confidence: 92%

Cyclooxygenase-2 as a biomarker with diagnostic, therapeutic, prognostic, and predictive relevance in small animal oncology

Szweda

Rychlik

Babińska

et al. 2020

Journal of Veterinary Research

View full text Add to dashboard Cite

In canine and feline populations, the number of neoplasm cases continues to increase around the world. Attempts are being made in centres of research to identify new biomarkers that speed up and improve the quality of oncological diagnostics and therapy in human and animal tumour patients. Cyclooxygenase-2 (COX-2) is a promising biomarker with increasing relevance to human oncology, but as yet with less application in veterinary oncology. The expression of COX-2 increases significantly during pathological processes involving inflammation, pain or fever. It is also overexpressed in humans presenting various types of tumours and in selected types of tumours in animals, particularly in dogs. This article discusses the expression of COX-2 in canine and feline tumours, the importance of COX-2 as a biomarker with diagnostic, therapeutic, prognostic and predictive relevance in oncology, and the clinical significance of inhibiting COX-2 overexpression in tumours.

show abstract

Section: Expression Of Cox-2 In Canine and Feline Tumourssupporting

confidence: 92%

Cyclooxygenase-2 as a biomarker with diagnostic, therapeutic, prognostic, and predictive relevance in small animal oncology

Szweda

Rychlik

Babińska

et al. 2020

Journal of Veterinary Research

View full text Add to dashboard Cite

show abstract

“…20 With regard to animal medicine, COX-2 expression has been demonstrated in intestinal carcinoma, 21 transitional cell carcinoma of the urinary bladder, 22 squamous cell carcinoma, 23 mammary and renal carcinoma, 24,25 and FISS. 26 COX-2 expression is induced by inflammatory stimuli and reflects cancer development and progression. 27 COX-2 staining in 61.9% of samples in this study and in 97% of samples in the study of Magi et al suggest a potential role of this enzyme in FISS progression.…”

Section: Discussionmentioning

confidence: 99%

“…27 COX-2 staining in 61.9% of samples in this study and in 97% of samples in the study of Magi et al suggest a potential role of this enzyme in FISS progression. 26 The expression of COX-2 in FISSs may contribute to the understanding of tumor behavior and may become a potential target therapy to treat FISSs with a non-steroidal anti-inflammatory drug.…”

Section: Discussionmentioning

confidence: 99%

Feline injection site sarcoma: immunohistochemical characteristics

Carneiro

Queiróz

Pinto

et al. 2018

Journal of Feline Medicine and Surgery

View full text Add to dashboard Cite

Objectives Feline injection site sarcoma (FISS) is a rapid growing locally aggressive tumor with a low metastatic rate. Its histologic features are clearly defined, but there are few studies regarding its immunohistochemical characteristics. The present study investigated the immunohistochemical characteristics of 21 cases of FISS. Methods FISSs from 12 male and nine female cats, 20 mixed-breed and one Siamese, were included in the study. After histopathological diagnosis, additional histologic sections were immunostained for vimentin, cytokeratin, desmin, S100 protein, viral feline leukemia virus (FeLV) particles, cyclooxygenase 2 (COX-2) and c-KIT. Positive and negative controls were adopted accordingly. Immunostainings were classified as positive and/or negative according to the number of positive cells from a total of 1000 cells per tumor section. Results Histopathologic diagnosis of the tumors revealed 18 (85.7%) fibrosarcomas and three (14.3%) other sarcomas; four fibrosarcomas (22.2%) were grade III, five (27.8%) were grade II and nine (50.0%) were grade I. Two sarcomas were grade III and one was grade II. Seventeen (81%) tumors were negative for desmin. All samples were positive for vimentin. Twenty tumors (95.2%) were positive for S-100 protein. Positivity for c-KIT was observed in four (19%) samples; COX-2 was positive in 13 (61.9%) and FeLV viral particles were positive in nine (42.9%) FISSs. Conclusions and relevance Immunohistochemical findings of FISSs revealed positive immunostainings for desmin, vimentin, S-100 protein, c-KIT, COX-2 and FeLV viral particles.

show abstract

“…In canines, COX‐2 protein overexpression has been identified in mesenchymal and epithelial tumours 44–51 . Additionally, in previous studies, the expression of COX‐2 detected by immunohistochemistry varied among FISSs, but the positive rates of COX‐2 expression in the FISS‐affected cats ranged between 0%–97% 30,34–36 . It has also been reported that COX‐2 expression could be detected in neoplastic cell lines of canine transitional cell carcinoma and feline oral squamous cell carcinoma by immunohistochemical staining, suggesting that COX‐2 inhibitors could be potential candidates for anticancer agents directly affecting neoplastic cells in dogs and cats 52 .…”

Section: Discussionmentioning

confidence: 91%

“…Cyclooxygenase‐2 (COX‐2) is an isoform of cyclooxygenase that converts arachidonic acid into prostaglandins, which are known as inflammatory promoters and are considered to collaboratively contribute not only to chronic inflammation but also to an adequate microenvironment for tumorigenesis 24,25 . Additionally, overexpression of COX‐2 has been reported in various human tumours, 26 canine 27–29 and feline, 29–33 including FISSs 34–36 . In human medicine, it has been reported that COX‐2 inhibitors could sensitize tumour cells to enhance their response to radiotherapy or chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Effects of selective cyclooxygenase‐2 inhibitor robenacoxib on primary cells derived from feline injection‐site sarcoma

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

Feline injection‐site sarcomas (FISSs) are highly invasive malignant mesenchymal neoplasms that arise from injection sites in cats. Although the tumorigenesis of FISSs is still uncertain, there is a consensus that FISS is associated with chronic inflammation caused by irritation of injection‐related trauma and foreign chemical substances. Chronic inflammation can provide a proper microenvironment for tumour development, which has been known as one of the risk factors of tumorigenesis in many tumours. To investigate the tumorigenesis of FISS and screen for its potential therapeutic targets, cyclooxygenase‐2 (COX‐2), an inflammation‐enhancing enzyme, was selected as a target for this study. In vitro experiments using FISS‐ and normal tissue‐derived primary cells and robenacoxib, a highly selective COX‐2 inhibitor, were performed. The results demonstrated that expression of COX‐2 could be detected in formalin‐fixed and paraffin‐embedded FISS tissues and FISS‐derived primary cells. Cell viability, migration and colony formation of FISS‐derived primary cells were inhibited, and cell apoptosis was enhanced by robenacoxib in a dose‐dependent manner. However, susceptibility to robenacoxib varied in different lines of FISS primary cells and was not completely correlated with COX‐2 expression. Our results suggest that COX‐2 inhibitors could be potential adjuvant therapeutics against FISSs.

show abstract

Immunohistochemical Expression of COX-2 in Feline Injection Site Sarcoma

Cited by 5 publications

References 0 publications

Cyclooxygenase-2 as a biomarker with diagnostic, therapeutic, prognostic, and predictive relevance in small animal oncology

Cyclooxygenase-2 as a biomarker with diagnostic, therapeutic, prognostic, and predictive relevance in small animal oncology

Feline injection site sarcoma: immunohistochemical characteristics

Effects of selective cyclooxygenase‐2 inhibitor robenacoxib on primary cells derived from feline injection‐site sarcoma

Contact Info

Product

Resources

About